The dawn of a new era of targeted lipid-lowering therapies.
Sign Up to like & getrecommendations! Published in 2022 at "European heart journal"
DOI: 10.1093/eurheartj/ehab841
Abstract: Lipid risk factors for cardiovascular disease depend in part on lifestyle, but optimum control of lipids often demands additional measures. Low-density lipoprotein (LDL) doubtless contributes causally to atherosclerosis. Recent human genetic findings have substantiated a… read more here.
Keywords: dawn new; new era; targeted lipid; lipid lowering ... See more keywords
Impact of lipid lowering therapies after an acute coronary syndrome, applied through telematic consultation, in a cohort of elderly patients
Sign Up to like & getrecommendations! Published in 2023 at "European Journal of Preventive Cardiology"
DOI: 10.1093/eurjpc/zwad125.100
Abstract: Type of funding sources: None. After Covid-19 pandemic, telematic cardiology consultations are a reality in most developed countries. However, the impact and safety of telemedicine in the elderly population needs to be clarified. Elderly patients… read more here.
Keywords: elderly patients; applied telematic; cardiology; lowering therapies ... See more keywords
Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
Sign Up to like & getrecommendations! Published in 2023 at "Diabetic Medicine"
DOI: 10.1111/dme.15083
Abstract: We investigated evidence from randomised, placebo‐controlled trials of novel glucose‐lowering therapies; sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i), dipeptidyl peptidase‐4 inhibitors (DPP4i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), on physical function in people with type 2 diabetes (T2D). read more here.
Keywords: controlled trials; randomised placebo; novel glucose; glucose lowering ... See more keywords
A New Beginning for Triglyceride Lowering Therapies.
Sign Up to like & getrecommendations! Published in 2019 at "Circulation"
DOI: 10.1161/circulationaha.119.038770
Abstract: The cardiovascular community has been debating for decades whether to treat mild-tomoderate hypertriglyceridemia. Results of the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)1 position this controversy as front matter for deliberation. For lipid… read more here.
Keywords: new beginning; triglyceride lowering; beginning triglyceride; lowering therapies ... See more keywords
Lipid-Lowering Therapies: Risks in Women and Evidence-Based Options.
Sign Up to like & getrecommendations! Published in 2018 at "Texas Heart Institute journal"
DOI: 10.14503/thij-18-6691
Abstract: C ardiovascular disease is the chief cause of death in women in the United States. Therefore, sex-based (biological) and gender-based (sociocultural) variations in the pathophysiology, symptoms, and response to pharmacologic interventions should be considered between… read more here.
Keywords: therapies risks; risks women; disease; lowering therapies ... See more keywords
Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc22-0888
Abstract: OBJECTIVE Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown. RESEARCH DESIGN AND METHODS We pooled data… read more here.
Keywords: physical activity; glucose lowering; lowering therapies; activity ... See more keywords
Is there a role of lipid-lowering therapies in the management of fatty liver disease?
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Hepatology"
DOI: 10.4254/wjh.v14.i1.119
Abstract: Atherogenic dyslipidemia is characterized by increased triglyceride-rich lipoproteins and low high-density lipoprotein cholesterol concentrations. It is highly prevalent in non-alcoholic fatty liver disease (NAFLD) and contributes to the increased cardiovascular risk associated with this condition.… read more here.
Keywords: fatty liver; role; management; lowering therapies ... See more keywords
LDL-C–lowering therapies reduce major vascular events in patients aged ≥75 y
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Internal Medicine"
DOI: 10.7326/acpj202104200-038
Abstract: SOURCE CITATION Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396:1637-43. 33186535. read more here.
Keywords: ldl lowering; vascular events; reduce major; lowering therapies ... See more keywords